OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 80 filers reported holding OCULAR THERAPEUTIX INC in Q4 2019. The put-call ratio across all filers is 0.24 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $73,195 | +88.2% | 13,889 | +0.4% | 0.00% | – |
| Q4 2022 | $38,888 | -39.2% | 13,839 | -10.1% | 0.00% | – |
| Q3 2022 | $64,000 | -85.0% | 15,394 | -41.0% | 0.00% | -100.0% |
| Q1 2021 | $428,000 | -12.5% | 26,083 | +10.5% | 0.00% | 0.0% |
| Q4 2020 | $489,000 | +244.4% | 23,600 | +26.9% | 0.00% | – |
| Q3 2020 | $142,000 | +91.9% | 18,600 | -0.6% | 0.00% | – |
| Q4 2019 | $74,000 | +48.0% | 18,713 | +14.1% | 0.00% | – |
| Q3 2019 | $50,000 | -3.8% | 16,400 | +37.8% | 0.00% | – |
| Q2 2019 | $52,000 | -42.2% | 11,900 | -18.5% | 0.00% | – |
| Q3 2017 | $90,000 | +25.0% | 14,600 | +87.2% | 0.00% | – |
| Q2 2017 | $72,000 | 0.0% | 7,800 | 0.0% | 0.00% | – |
| Q1 2017 | $72,000 | +188.0% | 7,800 | +160.0% | 0.00% | – |
| Q4 2016 | $25,000 | +257.1% | 3,000 | +200.0% | 0.00% | – |
| Q3 2016 | $7,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 5,618,861 | $116,310,000 | 100.00% |
| Opaleye Management Inc. | 6,510,000 | $134,758,000 | 17.60% |
| DELTEC ASSET MANAGEMENT LLC | 2,168,573 | $44,889,000 | 6.87% |
| Versant Venture Management, LLC | 1,465,384 | $30,333,000 | 3.15% |
| GREAT POINT PARTNERS LLC | 856,162 | $17,723,000 | 2.88% |
| Affinity Asset Advisors, LLC | 220,000 | $4,554,000 | 2.41% |
| Altium Capital Management LP | 303,174 | $6,276,000 | 2.34% |
| Endurant Capital Management LP | 290,465 | $6,013,000 | 2.17% |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 50,396 | $1,043,000 | 1.17% |
| Lisanti Capital Growth, LLC | 366,040 | $7,577,000 | 1.05% |